medicine-news-1/swine-flu-now-a-pandemic-48665-1/;msg18067;topicseen

Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4 WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2 Alberta companies delivering new products to the health & medical marketplace 2

[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening [0] Alberta companies delivering new products to the health & medical marketplace

Breaking Medicine Technology:NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2 NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3 Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2 Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3 Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2 BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 53494 1 BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 53494 2 Researchers effectively treat tumors with use of nanotubes 53492 1 Researchers effectively treat tumors with use of nanotubes 53492 2 Researchers effectively treat tumors with use of nanotubes 53492 3 Why anorexic patients cling to their eating disorder 53489 1 Why anorexic patients cling to their eating disorder 53489 2

[0] NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood [0] Vermillion Files Amended Plan of Reorganization and Exchanges Debt [0] Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland